Researchers find a common weakness in major gut pathogens (Links to an external site)

WashU Medicine researchers and collaborators at the University of Missouri identified a shared vulnerability across diarrhea-causing bacteria including E. coli (shown) and Shigella, a finding that could potentially lead to a single combination vaccine against these pathogens.

The bacteria enterotoxigenic E. coli and Shigella together cause hundreds of millions of infections each year and are among the leading causes of diarrheal death, especially in children. Decades of vaccine development efforts have come up short, in part because the usual vaccine targets vary too much from one strain to the next.

How obesity disrupts the body’s cellular messaging system (Links to an external site)

Clair Crewe, PhD

Lead author Clair Crewe, PhD, Assistant Professor of Medicine in WashU Medicine’s Division of Cell Biology and Physiology and Division of Endocrinology, Metabolism and Lipid Research, the Crewe Lab and collaborators from the Department of Pathology and Immunology and the Center for Human Nutrition are authors of a study published May 5, 2026, in Cell Metabolism.

Genetically modified hookworms produce and deliver therapeutics (Links to an external site)

WashU Medicine researchers genetically modified hookworms to produce and deliver a therapeutic antibody inside a host, a proof-of-concept that could lead to long-lasting treatments for chronic disease or exposure to toxins in remote settings. (Image courtesy of Makedonka Mitreva)

Hookworms, intestinal parasites that infect hundreds of millions of people in under-resourced tropical regions around the globe, have evolved to survive inside the human gut for years, secreting molecules that enable co-existence with their hosts. Now, researchers at Washington University School of Medicine in St. Louis have harnessed that biological mechanism for potential human benefit, […]

Millman receives grant to advance cell therapies for type 1 diabetes  (Links to an external site)

Jeffrey Millman, PhD

Jeffrey R. Millman, PhD, Professor of Medicine in the Division of Endocrinology, Metabolism & Lipid Research at WashU Medicine, has received research funding from Breakthrough T1D to support his project titled “Overcoming Production Barriers to Stem Cell-Islet Therapies Through Scalable Technologies.” The two-year grant supports efforts to address key challenges in bringing manufactured islet cell therapies for type […]

Researchers augment infection surveillance tool with AI, find enhanced patient safety (Links to an external site)

Abby Sung, MD

WashU Medicine infectious diseases researchers have developed a practical use of artificial intelligence to enhance patient safety, while potentially reducing costs and improving efficiency at hospitals. Abby Sung, MD, an assistant professor of medicine, and colleagues in the Division of Infectious Diseases, WashU McKelvey School of Engineering AI for Health Institute, and Barnes-Jewish Hospital (BJH) found that a large language model (LLM) can strengthen a semi-automated surveillance tool used by infection prevention. 

Goldberg co-authors study on obicetrapib in patients with heterozygous familial hypercholesterolemia (Links to an external site)

Anne Carol Goldberg, MD, FACP, Professor of Medicine in the Division of Endocrinology, Metabolism & Lipid Research

Anne Carol Goldberg, MD, FACP, Professor of Medicine in the Division of Endocrinology, Metabolism & Lipid Research at WashU Medicine, is a co-author of a study published February 27, 2026, in Nature Medicine. The article, titled “Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial,” explores a potential new option for people living […]

Soudah and collaborators review semaglutide’s metabolic and cognitive effects  (Links to an external site)

Hani Soudah, MD, PhD

On March 1, Hani Soudah, MD, PhD, Associate Professor of Medicine in the Division of Endocrinology, Metabolism, & Lipid Research at WashU Medicine, along with collaborators, published a new systematic review and meta-analysis examining the broader physiological effects of semaglutide titled “A Systematic Review and Meta-Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition.” 

Identifying how the body regulates fat breakdown during metabolic stress (Links to an external site)

Irfan Lodhi, PhD, Professor of Medicine in the Division of Endocrinology, Metabolism & Lipid Research at WashU Medicine

Irfan Lodhi, PhD, Professor of Medicine in the Division of Endocrinology, Metabolism & Lipid Research at WashU Medicine, and collaborators are authors of a study published January 8, 2026, in Nature Metabolism. The article, titled “A catecholamine-independent pathway controlling adaptive adipocyte lipolysis,” investigates how the body breaks down stable fat stores during conditions such as starvation, wasting and cachexia. 

Jennifer Alexander-Brett, MD, PhD Featured for COPD Research Advances (Links to an external site)

Jennifer Alexander-Brett, MD, PhD

Jennifer Alexander‑Brett, MD, PhD, Associate Professor of Medicine, has been featured in a recent Nature Biotechnology article highlighting major advances in targeting interleukin‑33 (IL‑33) signaling in chronic obstructive pulmonary disease (COPD). The article, “Newcomer anti‑IL‑33 makes strides in COPD,” underscores the growing impact of IL‑33–focused therapeutics and the importance of foundational biological insight in translating discovery to patient […]

Personalized vaccine shows promise against aggressive brain cancer (Links to an external site)

A WashU Medicine-led clinical trial conducted at Siteman Cancer Center has found that a personalized vaccine to treat glioblastoma is safe and could potentially improve outcomes. Trial participant Kim Garland (left) reviews a scan with the study’s primary investigator, Tanner Johanns, MD, PhD, a WashU Medicine oncologist.

A personalized vaccine to treat glioblastoma, a fast-growing and incurable brain cancer that affects four in 100,000 people in the U.S., is safe and elicits robust and broad immune responses that appears to increase recurrence-free survival in a subset of patients after surgery, according to an early-stage clinical trial co-led by researchers at Washington University […]

2026 Spring Cycle ICTS NIH Mock Study Section Recap (Links to an external site)

Wednesday, April 15, 2026, marks the 15th spring cycle of the ICTS NIH Mock Study Section. Through its Research Development Program, the ICTS offers NIH Mock Study Sections (MSS) that closely simulate an actual NIH study section. These sessions provide detailed, study section–style feedback on complete grant applications for clinical and translational R, K, and […]

Innovative CAR-T cell therapy receives FDA Breakthrough Therapy designation (Links to an external site)

An innovative cell-based immunotherapy developed by WashU Medicine researchers has received Breakthrough Therapy designation from the FDA. The novel CAR-T cell therapy is licensed to Wugen, a WashU Medicine startup based in the Cortex Innovation District in St. Louis (shown).

A cell-based immunotherapy designed to treat rare and aggressive types of blood cancer has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). Developed by researchers at Washington University School of Medicine in St. Louis, this innovative CAR-T cell therapy is licensed to Wugen, a WashU Medicine startup biotechnology company based […]

Global Health Researchers Find Care Disparities Among Asian Heart Failure Patients in US (Links to an external site)

Mark Huffman, MD, MPH, William Bowen Endowed Professor of Medicine and Co-Director of the Global Health Center, and Anubha Agarwal, MD, MSc an associate professor of medicine and Co-Director of the Program in Global Cardiovascular Health

WashU Cardiovascular Division Global Health researchers have published a new article on disparity on heart failure care for Asian patients in the U.S. Mark Huffman, MD, MPH, William Bowen Endowed Professor of Medicine and Co-Director of the Global Health Center, and Anubha Agarwal, MD, MSc an associate professor of medicine and Co-Director of the Program in Global Cardiovascular Health […]

Stopping GLP-1 drugs can quickly erase cardiovascular benefits (Links to an external site)

WashU Medicine researchers found that stopping GLP-1 drugs such as semaglutide and tirzepatide — even temporarily — elevates the risk of heart attack, stroke and death compared to staying on the medication continuously.

Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, approximately one in eight U.S. adults now take these medications, which also provide cardiovascular benefits. However, when patients stop taking these drugs, they not only regain weight, but, according to a new study, they also incur […]

Krings Published in Annals of Internal Medicine (Links to an external site)

Krings

James Krings, MD, MSCI, Assistant Professor of Medicine, was recently published in Annals of Internal Medicine. The study, “A New Approach to Reliever Therapy in Asthma: Implications of the U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline”.

GLP-1 medications get at the heart of addiction: study (Links to an external site)

WashU Medicine researchers find in a new study that GLP-1 use is tied to reductions in substance use disorders and serious outcomes across all types of addictive substances.

Researchers at Washington University School of Medicine in St. Louis show in a new study that GLP-1 medications may be effective at treating and preventing substance use disorders across all major addictive substances studied, suggesting these drugs target a common biological pathway underlying addiction.

Publication reviews 15 years of DOLF accomplishments and looks toward disease elimination (Links to an external site)

The Death to Onchocerciasis and Lymphatic Filariasis (DOLF) project at Washington University in St. Louis

The Death to Onchocerciasis and Lymphatic Filariasis (DOLF) project at Washington University in St. Louis recently celebrated 15 years of conducting clinical and translational research to test new treat­ments to support the elimination of two major neglected tropical diseases (NTDs), namely lymphatic filariasis (LF) and onchocerciasis (also known as river blindness).

Clinical considerations for thyroid dysfunction among older adults (Links to an external site)

Sina Jasim. MD, MPH, associate professor of medicine in the Division of Endocrinology, Metabolism & Lipid Research at WashU Medicine

Sina Jasim, MD, MPH, associate professor of medicine in the Division of Endocrinology, Metabolism & Lipid Research at WashU Medicine, and Maria Papaleontiou, MD, associate professor of internal medicine in the Division of Metabolism, Endocrinology, and Diabetes at the University of Michigan, have published a narrative review in Thyroid®, the official journal of the American Thyroid Association. 

Nasal vaccine combats bird flu infection in rodents (Links to an external site)

Researchers at WashU Medicine have developed a nasal vaccine against the highly pathogenic H5N1 avian influenza virus, or bird flu, which has jumped from wild birds to livestock to humans. When tested in rodents, the vaccine elicited a strong immune response and prevented infections in animals exposed to H5N1.

Since it was first detected in the U.S. in 2014, H5N1 avian influenza, commonly known as bird flu, has jumped from wild birds to farm animals and then to people, causing more than 70 human cases in the U.S. since 2022, including two fatalities. The virus continues to circulate among animals, giving it the opportunity […]

Immunotherapy reduces plaque in arteries of mice (Links to an external site)

An immunotherapy reduces plaque in the arteries of mice, offering a potential new strategy to treat cardiovascular disease, according to a study led by WashU Medicine researchers. An artery from an untreated mouse (top) shows more plaque (orange) than that of a mouse treated with the antibody-based immunotherapy (bottom).

Scientists have designed an immunotherapy that reduces plaque in the arteries of mice, presenting a possible new treatment strategy against heart disease. The antibody-based therapy could complement traditional methods of managing coronary artery disease that focus on lowering cholesterol through diet or medications such as statins, according to the findings of a new study led […]

Breath carries clues to gut microbiome health (Links to an external site)

WashU Medicine and Children’s Hospital of Philadelphia researchers found that an analysis of compounds exhaled in breath can be used to infer which microbes are living in the gut, paving the way for a rapid, non-invasive breath test to monitor and diagnose gut health issues.

The human gut is home to trillions of beneficial microbes that play a crucial role in health. Disruptions in this delicate community of bacteria and viruses — called the gut microbiome — have been linked to obesity, asthma and cancer, among other illnesses. 

WashU startups attract record-setting $1.7 billion in private-sector investment over past year (Links to an external site)

St. Louis-based biotech company Wugen, which is developing cell-based immunotherapies for hard-to-treat blood cancers, is among the WashU startups that collectively have attracted a record-setting total of $1.7 billion in private-sector investment over the past year.

Startup companies built on Washington University in St. Louis discoveries attracted a record $1.7 billion in private-sector investment over the past year, accelerating the commercialization of WashU innovations into life-changing diagnostics, therapeutics and medical devices. Among those innovations are a blood test to diagnose Alzheimer’s disease; immunotherapies to treat aggressive blood cancers; and an AI-based […]

Genetic analysis explains rare disease severity, points to possible treatment (Links to an external site)

Normal lung tissue is shown on the left. On the right is lung tissue from a person with primary ciliary dyskinesia with a CCDC39 mutation. A large mucus plug is visible in magenta, demonstrating the severe airway problems seen in such patients with these specific mutations. (Image: Brody lab/WashU Medicine)

Researchers at Washington University School of Medicine in St. Louis have uncovered why some patients with a rare genetic disorder called primary ciliary dyskinesia have worse lung problems than others with the same disorder. The discovery, published in Science Translational Medicine, suggests that gene therapy to restore a missing protein complex could help treat the […]

Prabhu Coauthors ACC Scientific Statement on inflammation and cardiovascular disease (Links to an external site)

Sumanth Prabu, MD, Lewin Distinguished Professor of Cardiovascular Diseases and Chief of the WashU Cardiovascular Division

Sumanth Prabu, MD, Lewin Distinguished Professor of Cardiovascular Diseases and Chief of the WashU Cardiovascular Division, co-authored the 2025 scientific statement published by the American College of Cardiology on the role of inflammation in cardiovascular disease. The new statement reviews residual inflammatory risk, screening & management, and new anti-inflammatory strategies.

Getting Ready for a Heart Failure Polypill, Well Before the Data Are In (Links to an external site)

Justin Chen, MD

A new paper in JACC: Advances delves into the factors that may affect implementation of a polypill for heart failure with reduced ejection fraction (HFrEF)—assuming one proves safe and effective—and outlines strategies for an eventual rollout. This exercise “just reinforces the idea, in addition to previous data showing therapeutic inertia and reluctance to use other […]

Hospitalists Contribute to Diabetic Ketoacidosis Protocol Improvements (Links to an external site)

Margo Girardi, MD, SFHM, and Gina LaRossa, MD

Margo Girardi, MD, SFHM, and Gina LaRossa, MD, contributed to an abstract and article that were featured in the Society of Hospital Medicine’s Journal of Hospital Medicine. The article, titled “Putting SQuID on the menu: A subcutaneous insulin protocol for diabetic ketoacidosis,” demonstrates how using a subcutaneous insulin protocol on hospitalist units for low-to-moderate severity DKA […]

Barriers Remain to Widespread Use of Polypills for CVD Therapy in High-Income Nations As Testing Continues (Links to an external site)

Anubha Agarwal, MD, MSc

The World Health Organization (WHO) added cardiovascular polypills to its 2023 Model List of Essential Medicines, and research continues to show that these medications are effective at preventing atherosclerotic cardiovascular disease (ACD) among various other forms of cardiovascular disease. Yet experts say obstacles remain to the adoption of these medications in high-income developed nations.

Meet the Researcher: Kameron Bradley (Links to an external site)

Kameron Bradley

A new preprint by Kameron Bradley of the Jeffrey Millman Lab, titled “Divergent Cell-Type Specific Hypoxia Responses in Human Stem Cell–Derived and Primary Islets,” sheds light on how different types of insulin-producing cells respond to oxygen deprivation, which is a common challenge in cell transplantation therapies for type 1 diabetes (T1D).

Leveraging AI to improve NF1 patient care: Comparing clinical entity extraction methods (Links to an external site)

Figure illustrating the general project workflow.

A new study published in the Journal of the American Medical Informatics Association (JAMIA) showcases how modern AI methods are advancing clinical and translational research in Neurofibromatosis type 1 (NF1). Conducted by Levi Kaster, BS, Ethan Hillis, MS, Inez Y. Oh, PhD, Elizabeth C. Cordell, MD, Randi E. Foraker, PhD, MA, Albert M. Lai, PhD, Stephanie M. Morris, […]